Aβ Specific Neutra™ Antibody Products

Amyloid beta (Aβ) is derived from non-amyloidogenic proteolysis of the amyloid precursor protein by β- / γ-secretase. Aβ has various forms such as Aβ monomer, Aβ oligomer, and Aβ amyloid plaques (see Figure 1). The deposition of Aβ is a critical event in the development of Alzheimer's disease (AD).

Fig. 1 The oligomerization and fiber formation of Aβ₄₀ and Aβ₄₂. ^{1, 3}

Biological Functions of Aβ

The different forms of Aβ interact with different cell surface receptors via the extracellular domain and activate downstream pathways (figure 2). These pathways play pivotal roles in the progression of Alzheimer's disease.

Fig. 2 Pathological functions of Aβ. ^{2, 3}

Aβ-based Clinical Strategies

Inhibition of Aβ oligomerization is the main traditional strategy for the treatment of AD by overexpressing β-degrading enzymes, using small molecule inhibitors of β- / γ-secretase, or blocking amyloid channels. Currently, Aβ antibodies that hydrolyze specific aggregates or reduce amyloid loads have developed into novel immunotherapy approaches for AD.

Table 1 provides some biological antibodies targeting Aβ and their ideal immunotherapy effects such as plaque clearance and reduced neurotoxicity.

Fig. 3 Milestone of the amyloid cascade hypothesis and its applications. ^{2, 3}

Creative Biolabs offers anti-Aβ antibodies that can be applied in all kinds of immunoassays including ELISA, IHC, and functional assays. These antibodies have good specificity to Aβ and are useful for the scientific research of the pathogenesis and treatment of AD.

REFERENCES

1. Hampel, Harald, et al. "The amyloid-β pathway in Alzheimer's disease." Molecular psychiatry 26.10 (2021): 5481-5503.
2. Zhang, Yun, et al. "Amyloid β-based therapy for Alzheimer's disease: Challenges, successes and future." Signal transduction and targeted therapy 8.1 (2023): 248.
3. Distributed under Open Access license CC BY 4.0, without modification.